Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis

Lancet. 2024 Jul 13;404(10448):117-120. doi: 10.1016/S0140-6736(24)01134-6. Epub 2024 Jun 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aminophenols / adverse effects
  • Aminophenols / therapeutic use
  • Benzodioxoles / adverse effects
  • Benzodioxoles / therapeutic use
  • Child
  • Child, Preschool
  • Chloride Channel Agonists* / adverse effects
  • Chloride Channel Agonists* / therapeutic use
  • Cystic Fibrosis* / drug therapy
  • Drug Combinations
  • Female
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Male
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Quinolines / adverse effects
  • Quinolines / therapeutic use
  • Sleep Wake Disorders* / chemically induced

Substances

  • Aminophenols
  • Benzodioxoles
  • Chloride Channel Agonists
  • Drug Combinations
  • elexacaftor, ivacaftor, tezacaftor drug combination
  • Indoles
  • Pyrazoles
  • Pyridines
  • Quinolines